Samuel Kyei, Randy Asiamah, Sandra Owusu, Nyaradzo Ellen Masango
{"title":"Microbial Contamination of Eye Drops: A Systematic Review and Meta-analysis.","authors":"Samuel Kyei, Randy Asiamah, Sandra Owusu, Nyaradzo Ellen Masango","doi":"10.1097/PTS.0000000000001334","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To profile the array of microbial contaminants of eye drops, both native and non-native to the ocular surface, and associated factors for contamination.</p><p><strong>Methods: </strong>Potentially relevant studies were retrieved from major bibliographic databases (PubMed, Scopus, and Web of Science). Data were extracted, and study-specific estimates of the contamination rates of topical ophthalmic solutions were combined using meta-analysis to obtain pooled results.</p><p><strong>Results: </strong>A total of 33 studies that evaluated the microbial contamination rate in 4600 samples were included in this study. The microbial contamination rate of in-use ophthalmic medications is 10% (95% CI: 6%-17%; PI: 0%-78%, I2=95.1%). The contamination rate among diagnostic eye drops is 13% (95% CI: 3%-42%; PI: 0%-98%, I2=95.6%), and the contamination rate among therapeutic eye drops is 10% (95% CI: 6%-17%; PI: 1%-63%, I2=94.9%). Staphylococcus spp. were the most prevalent gram-positive bacterial contaminants [3.55% (95% CI: 1.52%-8.04%; PI: 0.08%-63.46%), I2=93.2%], Escherichia coli, the most prevalent gram-negative contaminants [1.02% (95% CI: 0.50%-2.05%; PI: 0.16 to 6.04%), I2=24.8%], and Aspergillus spp., the most prevalent fungal contaminants [0.88% (95% CI: 0.31%-2.51%; PI: 0.03%-22.05%), I2=89.9%].</p><p><strong>Conclusion: </strong>There is a high rate of microbial contamination in topical ophthalmic solutions, which has implications for patient safety and the effort to stem avoidable blindness. Similar to injectable medications, we recommend using single-use vials for topical ophthalmic solutions, as opposed to multi-use vials, which are stored for a protracted period of time and used on multiple patients.</p>","PeriodicalId":48901,"journal":{"name":"Journal of Patient Safety","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Patient Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PTS.0000000000001334","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To profile the array of microbial contaminants of eye drops, both native and non-native to the ocular surface, and associated factors for contamination.
Methods: Potentially relevant studies were retrieved from major bibliographic databases (PubMed, Scopus, and Web of Science). Data were extracted, and study-specific estimates of the contamination rates of topical ophthalmic solutions were combined using meta-analysis to obtain pooled results.
Results: A total of 33 studies that evaluated the microbial contamination rate in 4600 samples were included in this study. The microbial contamination rate of in-use ophthalmic medications is 10% (95% CI: 6%-17%; PI: 0%-78%, I2=95.1%). The contamination rate among diagnostic eye drops is 13% (95% CI: 3%-42%; PI: 0%-98%, I2=95.6%), and the contamination rate among therapeutic eye drops is 10% (95% CI: 6%-17%; PI: 1%-63%, I2=94.9%). Staphylococcus spp. were the most prevalent gram-positive bacterial contaminants [3.55% (95% CI: 1.52%-8.04%; PI: 0.08%-63.46%), I2=93.2%], Escherichia coli, the most prevalent gram-negative contaminants [1.02% (95% CI: 0.50%-2.05%; PI: 0.16 to 6.04%), I2=24.8%], and Aspergillus spp., the most prevalent fungal contaminants [0.88% (95% CI: 0.31%-2.51%; PI: 0.03%-22.05%), I2=89.9%].
Conclusion: There is a high rate of microbial contamination in topical ophthalmic solutions, which has implications for patient safety and the effort to stem avoidable blindness. Similar to injectable medications, we recommend using single-use vials for topical ophthalmic solutions, as opposed to multi-use vials, which are stored for a protracted period of time and used on multiple patients.
期刊介绍:
Journal of Patient Safety (ISSN 1549-8417; online ISSN 1549-8425) is dedicated to presenting research advances and field applications in every area of patient safety. While Journal of Patient Safety has a research emphasis, it also publishes articles describing near-miss opportunities, system modifications that are barriers to error, and the impact of regulatory changes on healthcare delivery. This mix of research and real-world findings makes Journal of Patient Safety a valuable resource across the breadth of health professions and from bench to bedside.